EW Edwards Lifesciences Corporation Common Stock
$92,49
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 4, 2026
52 Haftlık Aralık
$72–$96
84% of range
Analist Derecelendirmesi
BUY
40 analysts
Fiyat Hedefi
$101
+9% upside
P/E (TTM)
57.4
ROE
10.6%
Net Kâr Marjı
17.7%
Edwards Lifesciences Corporation Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Devamını oku
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
EW Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$92.49
Piyasa Değeri
$61.04B
P/E (TTM)
57.4
EPS (TTM)
$1.83
Gelir (TTM)
$6.07B
Temettü Verimi
—
ROE
10.6%
D/E Borç/Özsermaye
0.1
52 Haftlık Aralık
$72 – $96
EW Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$6.07B
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$1.83
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$1.33B
2016-12-31
→
2025-12-31
Marjlar
17.7%
2016-12-31
→
2025-12-31
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
EW
Akran Ortalaması
P/E (TTM)
57.4
26.3
P/S (TTM) (F/S (TTM))
10.1
4.4
P/B (F/D)
5.9
5.3
EV / EBITDA
40.4
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
45.7
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
EW
Akran Ortalaması
Gross Margin (Brüt Kar Marjı)
78.0%
63.1%
Operating Margin (Faaliyet Kâr Marjı)
20.8%
—
Net Profit Margin (Net Kâr Marjı)
17.7%
15.6%
ROA
8.0%
7.6%
ROE
10.6%
15.0%
ROIC
9.6%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
EW
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
0.1
—
Current Ratio (Cari Oran)
3.7
1.7
Quick Ratio (Cari Oran)
2.7
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
EW
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
11.6%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
10.8%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
6.7%
—
EPS YoY (EPS YB)
-73.7%
—
Net Income YoY (Net Gelir Yıllık Bazda)
-74.3%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
EW
Akran Ortalaması
EW Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
40 analist
- Güçlü Al 13 32,5%
- Al 17 42,5%
- Tut 10 25,0%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
26 analist · 2026-08-19
Medyan
$101.50
Şimdi
$92.49
Düşük
$84.00
Yüksek
$110.00
Medyan hedef
$101.50
+9,7%
Ortalama hedef
$100.96
+9,2%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.02%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $0.78 | $0.76 | 0.02% |
| 31 Mart 2026 | $0.78 | $0.75 | 0.03% |
| 31 Aralık 2025 | $0.58 | $0.64 | -0.06% |
| 30 Eylül 2025 | $0.67 | $0.61 | 0.06% |
| 30 Haziran 2025 | $0.67 | $0.64 | 0.03% |
| 31 Mart 2025 | $0.64 | $0.61 | 0.03% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | — | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | — | 25.3 | 8.2% | 7.7% | 6.5% | — |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| GEHC | — | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
Bilanço 29
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
Nakit Akışı 18
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
Kârlılık 8
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
Büyüme Oranları 8
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | -1,173,800,000 | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 | 597,200,000 | 602,100,000 | 601,600,000 | -1,214,700,000 | 607,000,000 | 606,900,000 | 607,500,000 | -1,243,800,000 | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | -1,175,600,000 | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 | 598,100,000 | 604,300,000 | 604,100,000 | -1,221,300,000 | 609,500,000 | 610,300,000 | 610,900,000 | -1,256,400,000 | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
Bilanço 27
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
Nakit Akışı 13
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
Kârlılık 8
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
Likidite ve Solventlik 4
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
Değerleme (TTM) 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.47B | $6.15B | · | $5.88B | $5.69B | $5.52B | · | $5.32B | $5.21B | $5.12B | · | $5.06B | $5.19B | $5.26B | · | $5.34B | |
| Net Income TTM | $1.25B | $1.36B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.38B | $1.40B | · | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 42.3 | 34.4 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 30.9 | 41.7 | 35.2 | · | 35.5 | |
| P/S | 8.1 | 7.5 | · | 7.7 | 8.1 | 7.7 | · | 7.3 | 10.7 | 11.2 | · | 8.3 | 11.0 | 9.5 | · | 9.6 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| P / FCF | · | -2189.9 | · | · | · | 189.3 | · | · | · | -484.6 | · | · | · | 198.5 | · | · | |
| EV / EBITDA | 94.5 | 83.2 | · | 136.5 | 103.4 | 90.8 | · | 100.0 | 147.0 | 132.5 | · | 97.4 | 172.5 | 116.8 | · | 124.4 | |
| EV / FCF | · | -2044.2 | · | · | · | 174.6 | · | · | · | -475.3 | · | · | · | 195.9 | · | · | |
| EV / Revenue | 7.5 | 7.0 | · | 7.1 | 7.5 | 7.1 | · | 6.6 | 10.4 | 11.0 | · | 8.0 | 10.9 | 9.4 | · | 9.4 | |
| Earnings Yield | 2.4% | 2.9% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.2% | 2.4% | 2.8% | · | 2.8% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Brüt Kâr Marjı % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Faaliyet Kâr Marjı % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| Net Gelir | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Seyreltilmiş Hisse Başı Kâr | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Cari Oran | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| Cari Oran | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $1.33B | $290M | $643M | $974M | $1.41B |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 1.450 dosya · $30.4B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 152 (+6 önceki Ç'ye göre) | 97 (-10 önceki Ç'ye göre) | 459 (+11 önceki Ç'ye göre) | 452 (+4 önceki Ç'ye göre) | +26.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.402.739.018 | 37.615.952 | 11,20% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.389.175.425 | 26.411.402 | 7,86% | Hisse senetleri |
| STATE STREET CORP | $2.381.082.692 | 26.321.940 | 7,84% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $1.430.999.585 | 15.819.142 | 4,71% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $1.219.437.867 | 13.541.730 | 4,01% | Hisse senetleri |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1.135.640.991 | 12.554.068 | 3,74% | Hisse senetleri |
| Ninety One UK Ltd | $1.116.050.276 | 12.337.502 | 3,67% | Hisse senetleri |
| Aristotle Capital Management, LLC | $783.906.442 | 8.665.712 | 2,58% | Hisse senetleri |
| NORGES BANK | $757.492.410 | 8.373.783 | 2,49% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $693.526.113 | 8.660.416 | 2,28% | Hisse senetleri |
| FMR LLC | $607.177.379 | 6.712.109 | 2,00% | Hisse senetleri |
| Artisan Partners Limited Partnership | $599.361.052 | 6.625.703 | 1,97% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513.572.538 | 5.677.344 | 1,69% | Hisse senetleri |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434.208.000 | 4.800.000 | 1,43% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334.052.859 | 3.692.824 | 1,10% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $324.280.556 | 3.584.795 | 1,07% | Hisse senetleri |
| CITADEL ADVISORS LLC | $308.338.066 | 3.408.557 | 1,01% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $308.314.004 | 3.408.291 | 1,01% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $298.865.427 | 3.303.843 | 0,98% | Hisse senetleri |
| BROWN ADVISORY INC | $295.062.880 | 3.261.805 | 0,97% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $292.399.738 | 3.232.365 | 0,96% | Hisse senetleri |
| Holocene Advisors, LP | $283.979.721 | 3.139.285 | 0,93% | Hisse senetleri |
| NEUBERGER BERMAN GROUP LLC | $255.069.412 | 2.818.763 | 0,84% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250.776.107 | 2.772.232 | 0,83% | Hisse senetleri |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238.277.000 | 2.634.054 | 0,78% | Hisse senetleri |
| Mirova US LLC | $229.802.865 | 2.540.381 | 0,76% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $170.884.489 | 1.889.061 | 0,56% | Hisse senetleri |
| BlackRock, Inc. | $168.018.323 | 1.857.377 | 0,55% | Hisse senetleri |
| Assenagon Asset Management S.A. | $163.997.286 | 1.812.926 | 0,54% | Hisse senetleri |
| Point72 Asset Management, L.P. | $160.486.895 | 1.774.120 | 0,53% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $152.806.000 | 1.689.211 | 0,50% | Hisse senetleri |
| Swiss National Bank | $147.097.006 | 1.626.100 | 0,48% | Hisse senetleri |
| Woodline Partners LP | $141.123.209 | 1.560.062 | 0,46% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $140.351.128 | 1.551.434 | 0,46% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $137.670.984 | 1.521.899 | 0,45% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $131.472.173 | 1.453.357 | 0,43% | Hisse senetleri |
| Mitsubishi UFJ Asset Management Co., Ltd. | $126.120.870 | 1.394.217 | 0,42% | Hisse senetleri |
| Legal & General Group Plc | $121.108.845 | 1.338.811 | 0,40% | Hisse senetleri |
| ROYAL BANK OF CANADA | $119.193.000 | 1.317.637 | 0,39% | Hisse senetleri |
| Sumitomo Mitsui Trust Group, Inc. | $113.885.341 | 1.258.958 | 0,37% | Hisse senetleri |
| Quantinno Capital Management LP | $113.292.795 | 1.252.407 | 0,37% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $112.247.472 | 1.240.852 | 0,37% | Hisse senetleri |
| Liontrust Investment Partners LLP | $110.033.644 | 1.216.379 | 0,36% | Hisse senetleri |
| VANGUARD GROUP INC | $107.656.172 | 1.262.829 | 0,35% | Hisse senetleri |
| SEB Asset Management AB | $106.981.085 | 1.182.636 | 0,35% | Hisse senetleri |
| Liontrust Investment Partners LLP | $106.083.480 | 1.244.381 | 0,35% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $100.522.409 | 1.111.236 | 0,33% | Hisse senetleri |
| Polar Capital Holdings Plc | $99.945.636 | 1.104.860 | 0,33% | Hisse senetleri |
| RHUMBLINE ADVISERS | $99.213.696 | 1.096.770 | 0,33% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $92.822.996 | 1.026.122 | 0,31% | Hisse senetleri |
| PARNASSUS INVESTMENTS, LLC | $91.873.890 | 1.015.630 | 0,30% | Hisse senetleri |
| Bank of New York Mellon Corp | $91.654.072 | 1.013.200 | 0,30% | Hisse senetleri |
| National Pension Service | $90.349.187 | 998.775 | 0,30% | Hisse senetleri |
| California Public Employees Retirement System | $89.091.250 | 984.869 | 0,29% | Hisse senetleri |
| Caisse de depot et placement du Quebec | $87.523.397 | 967.537 | 0,29% | Hisse senetleri |
| ABN AMRO Bank N.V. | $83.573.385 | 924.314 | 0,28% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $82.454.109 | 911.498 | 0,27% | Hisse senetleri |
| Empower Advisory Group, LLC | $80.384.543 | 888.620 | 0,26% | Hisse senetleri |
| Meridiem Capital Partners LP | $77.697.994 | 858.921 | 0,26% | Hisse senetleri |
| Man Group plc | $76.372.212 | 844.265 | 0,25% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $75.525.054 | 834.900 | 0,25% | Hisse senetleri |
| Alyeska Investment Group, L.P. | $73.531.316 | 812.860 | 0,24% | Hisse senetleri |
| Nantahala Capital Management, LLC | $72.368.000 | 800.000 | 0,24% | Satım opsiyonu |
| CANADA PENSION PLAN INVESTMENT BOARD | $72.254.020 | 798.740 | 0,24% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $69.805.736 | 871.700 | 0,23% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $66.940.606 | 740.002 | 0,22% | Hisse senetleri |
| Bellevue Group AG | $66.871.108 | 739.234 | 0,22% | Hisse senetleri |
| Birch Hill Investment Advisors LLC | $66.522.203 | 735.377 | 0,22% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $64.772.074 | 716.030 | 0,21% | Hisse senetleri |
| TD Asset Management Inc | $61.560.472 | 680.527 | 0,20% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $61.491.904 | 679.769 | 0,20% | Hisse senetleri |
| UBS Group AG | $60.908.889 | 673.324 | 0,20% | Hisse senetleri |
| Candriam S.C.A. | $59.988.129 | 663.784 | 0,20% | Hisse senetleri |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $57.604.363 | 675.711 | 0,19% | Hisse senetleri |
| Integral Health Asset Management, LLC | $56.537.500 | 625.000 | 0,19% | Hisse senetleri |
| Ninety One North America, Inc. | $55.768.413 | 616.498 | 0,18% | Hisse senetleri |
| Robeco Institutional Asset Management B.V. | $55.270.246 | 610.991 | 0,18% | Hisse senetleri |
| Seilern Investment Management Ltd | $54.296.896 | 600.231 | 0,18% | Hisse senetleri |
| Nan Shan Life Insurance Co., Ltd. | $49.953.912 | 552.221 | 0,16% | Hisse senetleri |
| PFA Pension, Forsikringsaktieselskab | $49.175.025 | 543.611 | 0,16% | Hisse senetleri |
| BARCLAYS PLC | $49.135.520 | 543.174 | 0,16% | Hisse senetleri |
| Triodos Investment Management BV | $44.629.165 | 493.358 | 0,15% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $44.266.149 | 489.345 | 0,15% | Hisse senetleri |
| Mitsubishi UFJ Trust & Banking Corp | $43.182.890 | 477.370 | 0,14% | Hisse senetleri |
| APG Asset Management N.V. | $42.840.046 | 541.444 | 0,14% | Hisse senetleri |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $42.480.287 | 469.603 | 0,14% | Hisse senetleri |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $42.097.461 | 465.371 | 0,14% | Hisse senetleri |
| AVIVA PLC | $41.577.497 | 459.623 | 0,14% | Hisse senetleri |
| Balyasny Asset Management L.P. | $41.248.584 | 455.987 | 0,14% | Hisse senetleri |
| Korea Investment CORP | $40.486.097 | 447.558 | 0,13% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39.585.296 | 437.600 | 0,13% | Alım opsiyonu |
| NORDEA INVESTMENT MANAGEMENT AB | $37.761.927 | 418.322 | 0,12% | Hisse senetleri |
| STOREBRAND ASSET MANAGEMENT AS | $37.671.343 | 416.442 | 0,12% | Hisse senetleri |
| Qube Research & Technologies Ltd | $37.490.061 | 414.438 | 0,12% | Hisse senetleri |
| OFI INVEST ASSET MANAGEMENT | $36.480.086 | 458.427 | 0,12% | Hisse senetleri |
| Fisher Funds Management LTD | $35.971.057 | 397.646 | 0,12% | Hisse senetleri |
| LPL Financial LLC | $34.985.891 | 386.755 | 0,12% | Hisse senetleri |
| ABN AMRO INVESTMENT SOLUTIONS | $33.668.217 | 372.189 | 0,11% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $32.517.021 | 359.463 | 0,11% | Hisse senetleri |
| BLAIR WILLIAM & CO/IL | $32.206.687 | 356.032 | 0,11% | Hisse senetleri |
Şirket yöneticileri 48 içeriden öğrenenler · 18 yöneticiler · 8 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 27 Temmuz 2026 S | 8.916 | 0 | 8 | $-6.996.971 |
| Theodora Mistras | CVP, Chief Financial Officer | 09 Temmuz 2026 A | 99.920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 14 Mayıs 2013 A | 43.047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 30 Temmuz 2026 S | 21.534 | 0 | 4 | $-928.942 |
| Annette Bruls | CVP, EMEACLA | 11 Temmuz 2026 F | 20.628 | 0 | 0 | $0 |
| Andrew M. Dahl | SVP, Corporate Controller | 29 Mayıs 2026 S | 15.334 | 0 | 1 | $-48.893 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 28 Ekim 2014 M | 31.154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 13 Mayıs 2013 F | 4.035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 13 Mayıs 2013 S | 12.534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 13 Mayıs 2013 F | 56.071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 07 Mayıs 2013 F | 101.767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 27 Temmuz 2012 M | 1.124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 09 Mayıs 2012 A | 1.675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 13 Mayıs 2010 A | 16.687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 31 Ağustos 2007 S | 29.410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 10 Mayıs 2007 A | 15.300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 10 Mayıs 2007 A | 24.604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 04 Ağustos 2005 M | 3.349 | 0 | 0 | $0 |
| John T Cardis | Yönetim kurulu üyesi | 10 Ağustos 2016 S | 91.458 | 0 | 0 | $0 |
| Barbara J Mcneil | Yönetim kurulu üyesi | 04 Şubat 2016 S | 46.454 | 0 | 0 | $0 |
| Robert Alexander Ingram | Yönetim kurulu üyesi | 15 Mayıs 2015 A | 32.367 | 0 | 0 | $0 |
| Michael R Bowlin | Yönetim kurulu üyesi | 14 Kasım 2014 M | 81.751 | 0 | 0 | $0 |
| David E I Pyott | Yönetim kurulu üyesi | 09 Mayıs 2014 A | 53.582 | 0 | 0 | $0 |
| NEAL PHILIP M | Yönetim kurulu üyesi | 12 Ağustos 2008 M | 27.333 | 0 | 0 | $0 |
| Vernon R Loucks JR | Yönetim kurulu üyesi | 09 Mayıs 2008 A | 24.133 | 0 | 0 | $0 |
| Daniel J. Lippis | — | 11 Ağustos 2026 M | 40.034 | 0 | 12 | $-817.452 |
| Donald E Bobo JR | — | 27 Mayıs 2026 S | 98.611 | 0 | 12 | $-11.153.294 |
| Daveen Chopra | — | 22 Mayıs 2026 S | 44.324 | 0 | 3 | $-500.535 |
| Scott B. Ullem | — | 11 Mayıs 2026 M | 46.740 | 0 | 7 | $-3.875.008 |
| Leslie C. Davis | — | 08 Mayıs 2026 A | 9.834 | 0 | 0 | $0 |
| Ramona Sequeira | — | 08 Mayıs 2026 A | 6.779 | 0 | 0 | $0 |
| David T Feinberg | — | 08 Mayıs 2026 A | 9.087 | 0 | 0 | $0 |
| Kieran Gallahue | — | 08 Mayıs 2026 A | 4.315 | 0 | 0 | $0 |
| Nicholas J Valeriani | — | 08 Mayıs 2026 A | 84.423 | 0 | 0 | $0 |
| Heisz Leslie Stone | — | 08 Mayıs 2026 A | 34.199 | 0 | 1 | $-218.117 |
| Steven R Loranger | — | 08 Mayıs 2026 A | 8.997 | 0 | 0 | $0 |
| Paul A Laviolette | — | 08 Mayıs 2026 A | 17.552 | 0 | 0 | $0 |
| Larry L Wood | — | 18 Ağustos 2025 M | 206.900 | 0 | 0 | $0 |
| Catherine M. Szyman | — | 03 Eylül 2024 F | 81.287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | — | 07 Temmuz 2024 F | 184.686 | 0 | 0 | $0 |
| Robert W.A. Sellers | — | 11 Mayıs 2024 F | 17.081 | 0 | 0 | $0 |
| Michael A Mussallem | — | 02 Mayıs 2024 M | 4.486 | 0 | 0 | $0 |
| Martha H. Marsh | — | 12 Mayıs 2023 A | 31.880 | 0 | 0 | $0 |
| Huimin Wang | — | 08 Temmuz 2022 M | 99.381 | 0 | 0 | $0 |
| William J Link PHD | — | 08 Mayıs 2020 A | 11.349 | 0 | 0 | $0 |
| Wesley W Von Schack | — | 01 Ağustos 2019 S | 8.000 | 0 | 0 | $0 |
| Patrick B Verguet | — | 31 Mayıs 2017 M | 129.137 | 0 | 0 | $0 |
| Randall J Nelson | — | 30 Eylül 2003 A | — | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Açıklanmayan raporlama kişisi | 05 Nisan 2001 | — | İlk başvuru | Yönetim kurulu kampanyası | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 180 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IHI · iShares Trust | 4,29% | 1.607.851 SH | 08 Ağustos 2026 | Günlük |
| GDOC · Goldman Sachs ETF Trust | 2,98% | 6.939 NS | 31 Mayıs 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,11% | 10.000 NS | 31 Mayıs 2026 | N-PORT |
| ANEW · ProShares Trust | 2,02% | 1.801 NS | 31 Mayıs 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,83% | 2.435 NS | 30 Nisan 2026 | N-PORT |
| PJBF · PGIM ETF Trust | 1,75% | 2.374 NS | 29 Mayıs 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,75% | 10.488 NS | 31 Mayıs 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,58% | 137.940 SH | 08 Ağustos 2026 | Günlük |
| VOT · VANGUARD INDEX FUNDS | 1,14% | 4.411.246 SH | 08 Ağustos 2026 | Günlük |
| ALTL · Pacer Funds Trust | 0,94% | 10.780 NS | 30 Nisan 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,93% | 4.325 NS | 30 Nisan 2026 | N-PORT |
| SDG · iShares Trust | 0,90% | 17.447 SH | 08 Ağustos 2026 | Günlük |
| FFND · Northern Lights Fund Trust II | 0,88% | 10.459 NS | 31 Mayıs 2026 | N-PORT |
| IYH · iShares Trust | 0,83% | 341.366 SH | 08 Ağustos 2026 | Günlük |
| BKDV · BNY Mellon ETF Trust II | 0,81% | 134.666 NS | 30 Nisan 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,79% | 197.378 NS | 30 Nisan 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,79% | 22.410 NS | 30 Nisan 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 267.514 NS | 30 Nisan 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,77% | 1.733.147 SH | 08 Ağustos 2026 | Günlük |
| NULC · Nushares ETF Trust | 0,75% | 5.090 NS | 30 Nisan 2026 | N-PORT |
| RXL · ProShares Trust | 0,73% | 6.052 NS | 31 Mayıs 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,70% | 11.571 NS | 30 Nisan 2026 | N-PORT |
| IMCG · iShares Trust | 0,66% | 301.692 SH | 08 Ağustos 2026 | Günlük |
| IXJ · iShares Trust | 0,65% | 302.050 SH | 08 Ağustos 2026 | Günlük |
| TEC · Harbor ETF Trust | 0,61% | 491 NS | 30 Nisan 2026 | N-PORT |
| FWD · AB Active ETFs, Inc. | 0,56% | 187.544 NS | 31 Mayıs 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,56% | 4.857 NS | 30 Nisan 2026 | N-PORT |
| BRNY · EA Series Trust | 0,54% | 35.555 NS | 30 Nisan 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,53% | 24.654 NS | 31 Mayıs 2026 | N-PORT |
| SUSA · iShares Trust | 0,51% | 237.552 SH | 08 Ağustos 2026 | Günlük |
| VO · VANGUARD INDEX FUNDS | 0,50% | 12.477.902 SH | 08 Ağustos 2026 | Günlük |
| IWS · iShares Trust | 0,49% | 860.071 SH | 08 Ağustos 2026 | Günlük |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,42% | 44.305 NS | 30 Nisan 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 193.493 NS | 30 Nisan 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 3.768 NS | 30 Nisan 2026 | N-PORT |
| IWR · iShares Trust | 0,36% | 2.320.860 SH | 08 Ağustos 2026 | Günlük |
| IMCB · iShares Trust | 0,34% | 63.843 SH | 08 Ağustos 2026 | Günlük |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 286.558 NS | 30 Nisan 2026 | N-PORT |
| EVUS · iShares Trust | 0,31% | 12.935 SH | 08 Ağustos 2026 | Günlük |
| NBCR · Neuberger Berman ETF Trust | 0,30% | 30.404 NS | 31 Mayıs 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,29% | 156.342 SH | 08 Ağustos 2026 | Günlük |
| XOEF · iShares Trust | 0,28% | 720 SH | 08 Ağustos 2026 | Günlük |
| ESUM · Strategy Shares | 0,27% | 5.033 NS | 30 Nisan 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,27% | 189.108 NS | 30 Nisan 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0,24% | 31.226 NS | 30 Nisan 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,24% | 7.428 NS | 29 Mayıs 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 887 NS | 30 Nisan 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,22% | 15.544 NS | 30 Nisan 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 0,22% | 7.122 NS | 31 Mart 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,21% | 42.168 NS | 31 Mayıs 2026 | N-PORT |